NO. 81
CIMR Wednesday Lecture Series
Time:
Wednesday, Sep. 10 2025, 4:00 p.m.
Location:
Multi-Function Hall, 2nd Floor, North Basic Research Building
Host：
Shao-Cong Sun (孙少聪)
Chinese Institutes for Medical Research, Beijing
Speaker：
Xin Lin (林欣)
Professor
Tsinghua University School of Medicine
TITLE：
Developing TCR-based Chimeric Antigen Receptor STAR for Immunotherapy
ABSTRACT:
Chimeric antigen receptor T (CAR-T) cell therapies for B cell malignancies demonstrate high response rate and durable disease control. However, in the case of solid tumors, CAR-T cells have not shown the promising effect. In our study, we construct a two-chain chimeric receptor, termed as Synthetic T Cell Receptor and Antigen Receptor (STAR), which incorporates antigen-recognition domain of antibody and engages entire CD3 signaling machinery of T cell receptor (TCR). STAR triggers strong and sensitive TCR-like signaling upon antigen stimulation. We found that STAR combines the advantage of CAR and TCR, which can be used to target both cell surface antigen and MHC-presented neoantigen for cancer cells. Thus, STAR-T cells provide a powerful approach to treat tumors and autoimmune diseases.
SELECTED PAPERS
1. Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, Lin S, Zhao X, Lin X. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021 Mar 24; 13(586): eabb5191.
2. Huang D, Li Y, Rui W, Sun K, Zhou Z, Lv X, Yu L, Chen J, Zhou J, Liu V, Wang J, Lan X, Fu YX, Zhao X, Lin X. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 2024 Nov 26; 43(11): 114949.
3. Yu L, Zhou Z, Yu H, Liu Y, Huang D, Wang J, Lin X. Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy. Mol Ther. 2025 Apr 2; 33(4): 1552-1565.
10 Xitoutiao, Youanmen Wai, Fengtai District, Beijing 100069, China
010-86738999
cimr@cimrbj.ac.cn
中文
